Kadimastem To Collaborate With Merck Serono To Advance Combined Efforts In Neurodegenerative Disease Area
8/4/2014 11:11:36 AM
NESS ZIONA, Israel--(BUSINESS WIRE)--Israeli biotechnology company Kadimastem (TASE:KDST) reports that it has signed a collaboration agreement with Merck to carry out drug screening in the neurodegenerative diseases space for multiple sclerosis (MS), and potential other neurodegenerative diseases. Kadimastem will utilize its unique platform for Merck Serono, the biopharmaceutical division of Merck, for the screening of new compounds as potential new therapeutics.
Help employers find you! Check out all the jobs and post your resume.
comments powered by